Summary of included clinical trials by malignant target and bispecific product
| Malignant target . | BsAb . | No. of trials . | Lymphoma subtype (no. of trials) . | No. of patients . | All-grade infection, % (95% CI) . | Median length of follow-up, mo (IQR) . |
|---|---|---|---|---|---|---|
| CD20 | Epcoritamab | 7 | Aggressive (5), indolent (1), and B-cell NHL NOS (1) | 470 | 39 (29-47) | 11.4 (6.1-17.1) |
| Glofitamab | 7 | Aggressive (6) and B-cell NHL NOS (1) | 618 | 42 (30-53) | 10.6 (6-15) | |
| Mosunetuzumab | 6 | Aggressive (3), indolent (2), and B-cell NHL NOS (1) | 599 | 43 (47-50) | 12.5 (8-28.5) | |
| Odronextamab | 3 | Aggressive (1), indolent (1), and B-cell NHL NOS (1) | 414 | 59 (48-69) | 21 (NR) |
| Malignant target . | BsAb . | No. of trials . | Lymphoma subtype (no. of trials) . | No. of patients . | All-grade infection, % (95% CI) . | Median length of follow-up, mo (IQR) . |
|---|---|---|---|---|---|---|
| CD20 | Epcoritamab | 7 | Aggressive (5), indolent (1), and B-cell NHL NOS (1) | 470 | 39 (29-47) | 11.4 (6.1-17.1) |
| Glofitamab | 7 | Aggressive (6) and B-cell NHL NOS (1) | 618 | 42 (30-53) | 10.6 (6-15) | |
| Mosunetuzumab | 6 | Aggressive (3), indolent (2), and B-cell NHL NOS (1) | 599 | 43 (47-50) | 12.5 (8-28.5) | |
| Odronextamab | 3 | Aggressive (1), indolent (1), and B-cell NHL NOS (1) | 414 | 59 (48-69) | 21 (NR) |
NR, not reported; NHL, non-Hodgkin lymphoma; NOS, not otherwise specified.